CA 19-9 serum course and prognosis of pancreatic cancer

International Journal of Pancreatology

Volumn 20, Issue 3, 1996, Pages 155-161

  Safi, Farouk ^a   Schlosser, Wolfgang ^a   Falkenreck, Stephanie ^a   Beger, Hans G ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

CA 19 9; diagnostic and prognostic values; Pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; PANCREAS BIOPSY; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK;

EID: 0030476574     PISSN: 01694197     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02803763     Document Type: Article

References (27)

1. Moosa AR, Levin B. The diagnosis of early pancreatic cancer, the University of Chicago experience. Cancer 1981; 47: 1688-1697.
2. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Mol Genet 1979; 5: 957-972.
3. Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is ganglioside containing sialylated lact-N-fucopentaose II. J Biol Chem 1982; 257: 14,365-14,369.
4. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sery of patients as a mucin. Cancer Res 1983; 43: 5489-5492.
5. Safi F, Beger HG, Bittner R, Büchler M, Krautzberger W. CA 19-9 and pancreatic adenocarcinoma. Cancer 1986; 57: 779-783.
6. Hermanek P, Scheibe O, Spiessl B, et al. TNM-Klassifikation Maligner Tumoren. Springer-Verlag, Berlin; 1987.
7. Del Vilano BC, Brennan S, Brock P, Bucher C, Lui V, McClure M, Zurawaski VR. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983; 29: 549-552.
8. Kaplan E, Meier P. Nonparametric estimation from incomparable observations. J Am Stat Assoc 1958; 53: 457-481.
9. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
10. Armitage P. Statistical Methods in Medical Research. Wiley, New York; 1971.
11. Lindholm L, Holmgren J, Svennerholm L, Fredman P, Nilsson O, Persson B, Myrvold M, Lagergard T. Monoclonal antibodies against gastrointestinal tumor-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol 1983; 71: 178-181.
12. Koprowski H, Brockhaus M, Blaszczyk M. Lewis blood-type may affect the incidence of gastrointestinal cancer. Lancet 1982; 1: 1332,1333.
13. Tempero MA, Uchida E, Takasaki H. Relationship of carbohydrate antigen 19-9 and Lewis antigen in pancreatic cancer. Cancer Res 1987; 4: 5501-5503.
14. Rosen von A, Linder S, Harmenberg U, Pegert S. Serum levels of CA 19-9 and CA 50 in relation of lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas 1993; 8: 160-165.
15. Malfertheiner P, Büchler M, Kraus C, Ditschuneit H. Laktoferrin bei chronischer Pankreatitis, Pankreas Karzinom und entzündlicher Darmerkrankung. Verh Dtsch Ges Inn Med 1984; 90-96.
16. Reddi K. Clinical significance of human ribonuclease, in Clinical Features Early Diagnosis of Pancreatic Cancer, Kawai H, ed, Igaku-Shion, New York, 1980; pp. 35-41.
17. Podolsky DK, McPhee MS, Alpert E, Warshaw AL, Isselbacher KJ. Galactosyltransferase isoenzyme II in the detection of pancreatic cancer: comparison with radiologic, endoscopie and serologic cancer tests. N Engl J Med 1981; 304: 1313-1317.
18. Mahvi D, Meyers W, Bast R. Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. Ann Surg 1985; 202: 440-445.
19. Ohshio G, Manabe T, Watanabe Y, Endo K, Kudo H, Suzuki t, Tobe T. Comparative studies of DU-PAN-2, carcino-embryonic antigen, and CA 19-9 in ther serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am J Gastroenterol 1990; 85: 1370-1376.
20. Toshkov I, Mogaki M, Kazakoff K, Pour PM. The patterns of coexpression of tumor-associated antigens CA 19-9, TAG-72, and DU-PAN-2 in human pancreatic cancer. Int J Pancreatol 1994; 15: 97-103.
21. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Randall K, Sninsky JJ. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1993; 53: 2472-2474.
22. Tabata T, Fujimori T, Maeda S, Masahiro Y, Saitoh Y. The role of ras mutation in pancreatic cancer, precancerous lesions, and chronic pancreatitis. Int J Pancreatol 1993; 14(3): 237-244.
23. Masson P, Andren-Sandberg A. Crude isolation of DNA from unselected human pancreatic tissue and amplification by the polymerase chain reaction of Ki-ras oncogene to detect point mutations in pancreatic cancer. Acta Oncol 1992; 31(4): 421-424.
24. Kondo H, Sugano K, Fukayama N, Kyoguku A, Nose H, Shimada K, Ohkura H, Ohtsu A, Yoshida S, Shimosato Y. Detection of point mutations in the K-ras oncogene at cadon 12 in pure pancreatic juice for diagnosis of pancreatic carcinoma. Cancer 1994; 73: 1589-1594.
25. Haglund C, Roberts PJ, Kuusela P, Scheinin TM, Mäkelä O, Jalanko H. Evaluation of CA 19-9 as a serum tumor marker in pancreatic cancer. Br J Cancer 1986; 53: 197-202.
26. Safi F, Roscher R, Beger HG. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9. Hepatogastroenterology 1989; 36: 419-423.
27. Frebourg T, Bercoff E, Manchon N. The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer 1988; 62: 2287-2290.